Recent news highlights Tilray's Q1 loss and revenue challenges, ongoing strategic acquisitions, and market positioning amid cannabis industry consolidation and regulatory developments.

• Tilray reported a Q1 net loss and missed revenue estimates, reflecting ongoing financial challenges [N1].
• The company completed the acquisition of BrewDog, expanding its global beverage platform [S1].
• Tilray entered a multi-year licensing agreement with Carlsberg to produce and distribute Carlsberg-branded beers in the U.S. starting in 2027 [S1].
• The acquisition of Lyphe Group aims to enhance Tilray's medical cannabis access and digital pharmacy capabilities in the UK [S1].
• Tilray's cannabis segment revenue includes significant contributions from Canadian adult-use cannabis and international markets [S1].
• The company is focused on cost management and operational efficiencies to improve margins and maintain financial strength [S1].
• Regulatory and competitive risks remain significant, with ongoing monitoring of U.S. federal cannabis rescheduling and legal challenges [S1].
• Tilray's revolving credit facility has amended covenants and borrowing restrictions, impacting liquidity management [S2].

Tilray's diversified business model across cannabis, beverage, wellness, and distribution segments provides multiple revenue streams and growth avenues. Its leadership in the U.S. craft beer market and Canadian cannabis market, combined with global expansion through acquisitions, positions it to capitalize on evolving consumer preferences and regulatory changes. The company's investments in innovative cannabis products and digital medical platforms may enhance patient and consumer access. Strong liquidity and focus on cost management support operational flexibility.

Tilray faces significant risks including integration challenges from recent acquisitions, regulatory uncertainties across multiple jurisdictions, and intense competition from both illicit and well-capitalized market participants. The company's history of net losses and financial covenant restrictions on its credit facility may constrain strategic initiatives. Supply chain disruptions, product liability risks, and evolving U.S. regulations on hemp and cannabis products add operational complexity. Market price volatility and macroeconomic factors may impact financial stability and investor sentiment.

Tilray's moat is built on its diversified portfolio of strong, consumer-connected brands across cannabis, beverage, and wellness sectors, including leadership positions in the U.S. craft beer market and Canadian cannabis market. Its global distribution network and EU-GMP certified medical cannabis supply chain provide competitive advantages in international markets. Strategic acquisitions like BrewDog and Lyphe Group enhance its product offerings and geographic reach. The company's focus on innovation, brand loyalty, and operational scale supports its market position amid competitive and regulatory challenges.

• Acquisition Integration and Operational Disruption: Tilray may not realize anticipated benefits from acquisitions such as BrewDog and Lyphe Group and could face challenges integrating these businesses, potentially disrupting operations.
• Regulatory Compliance and Licensing: The company's operations depend on maintaining regulatory approvals, licenses, and permits across multiple jurisdictions, with changes in cannabis, hemp, or other laws potentially adversely affecting its business.
• Competition: Tilray faces significant competition in cannabis and beverage markets from illicit participants and large, well-capitalized competitors, which could pressure sales and margins.
• Supply Chain and Production Risks: Risks include natural disasters, crop failures, supply disruptions, and increased input costs that could impact production and distribution.
• Product Liability and Reputation: Potential recalls, contamination, product liability claims, or adverse health effects could harm consumer demand and the company's reputation.
• Financial Covenant Restrictions: Restrictions and amended covenants on Tilray's revolving credit facility may limit borrowing availability and strategic flexibility if financial covenants are not met.
• Cybersecurity and IT Risks: Cybersecurity incidents or IT failures could disrupt operations, cause financial losses, and expose the company to liability.
• Market and Macroeconomic Risks: Macroeconomic conditions, inflation, tariffs, foreign exchange fluctuations, and geopolitical instability may adversely affect business results and financial condition.

• Tilray Brands, Inc. is a Delaware corporation headquartered in Leamington and New York with operations in Canada, the United States, Europe, Australia, and Latin America.
• The company operates as a global lifestyle consumer products company at the nexus of cannabis, beverage, wellness, and entertainment.
• Tilray's portfolio includes well-known brands such as SweetWater Brewing, Montauk Brewing, BrewDog, Shock Top, 10 Barrel, Breckenridge Brewery, Blue Point Brewing, Breckenridge Distillery, Revolver, Terrapin, Broken Coast, Good Supply, Redecan, Solei, Tilray, ARX, XMG, Manitoba Harvest, and Hi-Ball.
• In the U.S., Tilray is the 4th largest craft brewer.
• In Canada, Tilray leads the cannabis market with the highest cannabis revenue.
• Manitoba Harvest is a leader in the hemp-based food category in the U.S.
• Internationally, Tilray distributes medical cannabis products in over 20 countries across five continents through subsidiaries and distributors.
• Fiscal year ended May 31, 2026, total net revenue was $915.5 million, with 28% from beverage, 29% from cannabis, 36% from distribution, and 7% from wellness segments.
• The cannabis segment revenue was $268.3 million, with sales channels including Canadian medical cannabis, Canadian adult-use cannabis, wholesale cannabis, and international cannabis.
• Tilray completed the acquisition of BrewDog in early 2026, expanding its beverage platform globally.
• The company entered into a multi-year licensing agreement with Carlsberg Group to produce and distribute Carlsberg-branded beers in the U.S. starting January 1, 2027.
• Tilray acquired Lyphe Group, a UK-based medical cannabis clinic and digital pharmacy platform, in April 2026 to enhance medical cannabis access and digital capabilities.
• The company focuses on building global brands, developing innovative cannabis products, growing beverage and hemp-based food businesses, expanding medical cannabis availability globally, and optimizing global operations for cost efficiency.
• Tilray's liquidity as of August 31, 2026, includes $215 million in cash and equivalents, $3 million in short-term investments, current assets of $808 million, current liabilities of $431 million, a current ratio of 1.88, and a cash ratio of 0.51.
• For the quarter ended August 31, 2026, Tilray reported a net loss of $43.1 million and basic and diluted EPS of -$0.32.
• The company faces risks including integration challenges from acquisitions, regulatory dependencies across jurisdictions, competition in cannabis and beverage markets, supply chain risks, product liability, litigation, cybersecurity threats, evolving U.S. regulations on hemp and cannabis products, workforce management, history of net losses, financial covenant restrictions on credit facilities, macroeconomic and geopolitical risks, and market price volatility.
• Tilray's revolving credit facility has restrictions and amended covenants as of October 2026, with borrowing availability limited until covenant tests resume.
• The company is focused on cost structure management, margin expansion, and maintaining a strong financial position to support growth and shareholder value creation.